Feasibility
Studies currently in Feasibility - Blackpool
Embedded Files
Last content update - 21/09/2022
Please contact the Ella.riedel@nhs.net for more information on studies in feasibility
Mithridate
Mithridate
Specialty: Haematology
IRAS No: 248335
Estimated Opening: Sept 2022
Description: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera
ASCEND 2
ASCEND 2
Specialty: CancerSeek Testing
IRAS No: 311132
Estimated Opening: October 2022
Description: The purpose of this study is to obtain clinically characterized whole blood specimens from participants with new or suspected diagnosis of (cancer subjects) and from participants who do not have a diagnosis of cancer (healthy subjects) to develop and refine assays, such as CancerSEEK for cancer in the blood. CancerSEEK is a blood test, consisting of multiple assays, that is under development and designed to detect multiple types of cancer at the earliest stages possible.
STATIC (Flair)
STATIC (Flair)
Specialty: Haematology/ Leukemia
IRAS No: 1003615
Estimated Opening: October/November 2022
Description: A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)
MajesTEC- 7
MajesTEC- 7
Specialty: Haematology
IRAS No: 131272
Estimated Opening:
Description: A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
MomumenTAL 3
MomumenTAL 3
Specialty: Haematology
IRAS No:
Estimated Opening:
Description: A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
ENHANCE 3
ENHANCE 3
Specialty: Haematology/ Leukemia
IRAS No: 1004331
Estimated Opening: October 2022
Description: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Specialty:
IRAS No:
Estimated Opening:
Description:
Specialty:
IRAS No:
Estimated Opening:
Description:
Report abuse